Biokin Pharmaceutical's Innovative Drug BL-ARC002 Injection Receives Clinical Trial Authorization

Stock News

Mar 22

Sichuan Biokin Pharmaceutical Co., Ltd. (688506.SH) has announced that it recently received formal approval from the National Medical Products Administration (NMPA) for the clinical trial of its self-developed innovative drug, BL-ARC002 injection. According to the announcement, BL-ARC002 utilizes antibody-mediated precision targeting delivery technology combined with the potent tumor-killing capability of radionuclides. Compared to traditional radionuclide conjugate drugs, it demonstrates stronger target specificity, higher tumor enrichment, and is expected to exhibit improved resistance to drug resistance.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1164756025"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1164756025\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1164756025?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-22 15:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1164756025","market":"fut","top_or_hot":-1,"title":"Biokin Pharmaceutical's Innovative Drug BL-ARC002 Injection Receives Clinical Trial Authorization","media":"Stock News","content":"<p>Sichuan Biokin Pharmaceutical Co., Ltd. (688506.SH) has announced that it recently received formal approval from the National Medical Products Administration (NMPA) for the clinical trial of its self-developed innovative drug, BL-ARC002 injection. According to the announcement, BL-ARC002 utilizes antibody-mediated precision targeting delivery technology combined with the potent tumor-killing capability of radionuclides. Compared to traditional radionuclide conjugate drugs, it demonstrates stronger target specificity, higher tumor enrichment, and is expected to exhibit improved resistance to drug resistance.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biokin Pharmaceutical's Innovative Drug BL-ARC002 Injection Receives Clinical Trial Authorization</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiokin Pharmaceutical's Innovative Drug BL-ARC002 Injection Receives Clinical Trial Authorization\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-22 15:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Sichuan Biokin Pharmaceutical Co., Ltd. (688506.SH) has announced that it recently received formal approval from the National Medical Products Administration (NMPA) for the clinical trial of its self-developed innovative drug, BL-ARC002 injection. According to the announcement, BL-ARC002 utilizes antibody-mediated precision targeting delivery technology combined with the potent tumor-killing capability of radionuclides. Compared to traditional radionuclide conjugate drugs, it demonstrates stronger target specificity, higher tumor enrichment, and is expected to exhibit improved resistance to drug resistance.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02615","symbol_name":"百利天恒","start_time":0,"source_url":"","article_id":"1164756025","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1164756025","pubTimestamp":1774165450,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Sichuan Biokin Pharmaceutical Co., Ltd. (688506.SH) has announced that it recently received formal approval from the National Medical Products Administration (NMPA) for the clinical trial of its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"91194":"临工重机股份有限公司（临时代码）","159992":"创新药","688506":"百利天恒","02615":"百利天恒","06978":"永泰生物-B","BK1574":"生物医药B类股","LU1815336091.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AUP\" (USD) INC","BK0239":"医药制造","BK1161":"生物科技","LU0757428866.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AE\" (USD) ACC","BL":"Blackline Inc.","BK4023":"应用软件"},"translate_title":"百奥金药业创新药BL-ARC002注射液获临床试验授权","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"91194":1,"159992":1,"688506":1,"06978":1,"BL":1,"02615":1},"content_text":"Sichuan Biokin Pharmaceutical Co., Ltd. (688506.SH) has announced that it recently received formal approval from the National Medical Products Administration (NMPA) for the clinical trial of its self-developed innovative drug, BL-ARC002 injection. According to the announcement, BL-ARC002 utilizes antibody-mediated precision targeting delivery technology combined with the potent tumor-killing capability of radionuclides. Compared to traditional radionuclide conjugate drugs, it demonstrates stronger target specificity, higher tumor enrichment, and is expected to exhibit improved resistance to drug resistance.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}